Home » Stocks » CERS

Cerus Corporation (CERS)

Stock Price: $5.78 USD -0.36 (-5.87%)
Updated May 10, 2021 2:07 PM EDT - Market open
Market Cap 1.03B
Revenue (ttm) 119.17M
Net Income (ttm) -60.85M
Shares Out 168.82M
EPS (ttm) -0.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $5.78
Previous Close $6.14
Change ($) -0.36
Change (%) -5.87%
Day's Open 6.06
Day's Range 5.69 - 6.15
Day's Volume 1,620,049
52-Week Range 5.05 - 8.87

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Cerus (CERS) delivered earnings and revenue surprises of -11.11% and 8.74%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 days ago - Zacks Investment Research

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2021. Recent developments and highlights include: First quarter...

5 days ago - Business Wire

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2021 financial results will be released on Tuesday, May 4, 2021, after the close of the stock ma...

2 weeks ago - Business Wire

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: KOS, TRUE, LIVX, PNNT
2 months ago - 24/7 Wall Street

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that William ‘Obi' Greenman, Cerus' president and chief executive officer, and Kevin D. Green, Cerus' chief financial o...

2 months ago - Business Wire

Growth-oriented investors may be interested in the following small-cap stocks, as they represent businesses whose trailing 12-month earnings per share improved significantly on a year-over-year basis.

Other stocks mentioned: QTT, SYKE
2 months ago - GuruFocus

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and year ended December 31, 2020. Recent developments and highlights include: ...

2 months ago - Business Wire

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) and Shandong Zhongbaokang Medical Implements Co. Ltd. (ZBK) today announced that they are forming a joint venture (JV) with the intent ...

2 months ago - Business Wire

On Thursday, February 25, Cerus (NASDAQ:CERS) will release its latest earnings report. Benzinga's outlook for Cerus is included in the following report.

2 months ago - Benzinga

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full year 2020 financial results will be released on Thursday, February 25, 2021, after the...

2 months ago - Business Wire

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that William ‘Obi' Greenman, Cerus' president and chief executive officer, and Kevin D. Green, Cerus' chief financial o...

3 months ago - Business Wire

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today preliminary product revenue for the fourth quarter and full year 2020 and provided 2021 product revenue guidance. Cerus...

3 months ago - Business Wire

Cerus' FDA & CE approved Intercept pathogen reduction platform for platelets and plasma gathering momentum as FDA Guidelines require compliance with new blood safety measures by March 31, 2021. Cerus' p...

4 months ago - Seeking Alpha

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that its distribution partner, Companhia Energética Integrada (CEI), was awarded a three-year contract with the HemoMin...

4 months ago - Business Wire

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced the oral presentation of a clinical study: “Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients ...

5 months ago - Business Wire

Does Cerus (CERS) have what it takes to be a top stock pick for momentum investors? Let's find out.

5 months ago - Zacks Investment Research

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that the US Food and Drug Administration (FDA) has granted approval of the INTERCEPT Blood System for Cryoprecipitation...

5 months ago - Business Wire

Cerus (CERS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

5 months ago - Zacks Investment Research

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that William ‘Obi' Greenman, Cerus' president and chief executive officer, and Kevin D. Green, Cerus' chief financial o...

5 months ago - Business Wire

Cerus Corporation (CERS) CEO Obi Greenman on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Cerus (CERS) delivered earnings and revenue surprises of 33.33% and 2.20%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2020. Recent developments and highlights include: Q3 2020 T...

6 months ago - Business Wire

Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today that its third quarter 2020 financial results will be released on Thursday, October 29, 2020, after the close of the sto...

6 months ago - Business Wire

Cerus Inks FDA Contract, And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: GOSS
6 months ago - Seeking Alpha

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today it was awarded a five-year contract with the U.S. Food and Drug Administration (FDA) for the development of next-generat...

6 months ago - Business Wire

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today its lineup of abstract presentations at the AABB 2020 Virtual Annual Meeting, which will take place on October 3rd throu...

7 months ago - Business Wire

The pandemic highlights how far medical science has come. It also highlights how exciting the future is.

Other stocks mentioned: ADMA, AZN, BNTX, LMNL, PFE, SONN
8 months ago - InvestorPlace

Convalescent plasma stocks moved northward following FDA's emergency plasma authorization for COVID-19 treatment. Here're three of them that should be on your watch list -

Other stocks mentioned: KMDA, TTOO
8 months ago - Zacks Investment Research

Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use of investi...

Other stocks mentioned: ADMA, GRFS, KMDA, LMNL, SONN, THMO, TTOO
8 months ago - Benzinga

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today that INTERCEPT Blood Systems disposable kit shipments have surpassed 7.5 million treatable platelet and plasma doses glo...

9 months ago - Business Wire

Cerus Corporation (CERS) CEO Obi Greenman on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Cerus (CERS) delivered earnings and revenue surprises of 10.00% and 0.01%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2020.

9 months ago - Business Wire

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced it has been awarded a five-year tender by the Hong Kong Red Cross Blood Transfusion Services (BTS) for INTERCEPT Blood S...

9 months ago - Business Wire

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today that its second quarter 2020 financial results will be released on Tuesday, August 4, 2020, after the close of the stock...

9 months ago - Business Wire

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today study results demonstrating that the INTERCEPT Blood System inactivates SARS-CoV-2, the causative agent for COVID-19, in...

10 months ago - Business Wire

Is (CERS) Outperforming Other Medical Stocks This Year?

10 months ago - Zacks Investment Research

Cerus CEO on convalescent plasma, blood centers being the pandemic's 'unsung heroes'

YouTube video

Biotech company Cerus CEO Obi Greenman discussed early findings of using plasma to fight Covid-19.

10 months ago - CNBC Television

Cerus (CERS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

11 months ago - Zacks Investment Research

Cerus: Surging During The COVID-19 Pandemic

11 months ago - Seeking Alpha

Cerus Corporation (CERS) CEO Obi Greenman on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Cerus (CERS) delivered earnings and revenue surprises of 0.00% and 5.74%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Cerus Corporation (CERS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

1 year ago - Zacks Investment Research

Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Cerus Corporation (CERS).

1 year ago - Zacks Investment Research

Cerus: Looks Ready To Breakout Following Another Positive Earnings Report

1 year ago - Seeking Alpha

Cerus Corporation (CERS) CEO Obi Greenman on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Monday morning brought a huge sell-off in the market as more and more people are concerned about the growing impact of this new coronavirus.

Other stocks mentioned: AHPI, APT, BCRX, CODX, DYAI, INO, LAKE ...
1 year ago - 24/7 Wall Street

The newest coronavirus out of China has resulted in a rising interest in biotechs that may be able to produce a vaccine or treatment with a short turnaround.

1 year ago - 24/7 Wall Street

About CERS

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma that is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells... [Read more...]

Industry
Biotechnology
IPO Date
Jan 30, 1997
CEO
William Greenman
Employees
254
Stock Exchange
NASDAQ
Ticker Symbol
CERS
Full Company Profile

Financial Performance

In 2020, Cerus's revenue was $114.25 million, an increase of 21.83% compared to the previous year's $93.77 million. Losses were -$59.86 million, -15.98% less than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Cerus stock is "Strong Buy." The 12-month stock price forecast is 9.10, which is an increase of 57.58% from the latest price.

Price Target
$9.10
(57.58% upside)
Analyst Consensus: Strong Buy